JO3470B1 - مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv - Google Patents

مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv

Info

Publication number
JO3470B1
JO3470B1 JOP/2013/0284A JOP20130284A JO3470B1 JO 3470 B1 JO3470 B1 JO 3470B1 JO P20130284 A JOP20130284 A JO P20130284A JO 3470 B1 JO3470 B1 JO 3470B1
Authority
JO
Jordan
Prior art keywords
reverse transcriptase
hiv reverse
transcriptase inhibitors
pyrimidin
phenoxy
Prior art date
Application number
JOP/2013/0284A
Other languages
English (en)
Inventor
Burgey Christopher
Luo Yunfu
Lei Zhiyu
Han Yongxin
Patel Mehul
Li Yaozong
L Arrington Kenneth
Xu Jiayi
Gilfillan Robert
Sing Li Chun
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of JO3470B1 publication Critical patent/JO3470B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بمركبات لها الصيغة (1): </span> <img src="file:///C:/Users/Darwish.Q/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /> عبارة عم مثبطات إنزيم ترانسكريبتاز العكسي ل <span dir="LTR">HIV</span> حيث تكون <span dir="LTR">R1 </span> و <span dir="LTR">R2</span> و <span dir="LTR"> RE</span> و <span dir="LTR">L</span> و <span dir="LTR">M</span> و <span dir="LTR">Z</span> كما هي محددة في هذا الطلب. تتسم المركبات التي لها الصيغة 1 و الأملاح و العقاقير الأولية المقبولة صيدلانيا منها بفائدتها في تثبيط إنزيم ترانسكربيتاز العكسي ل <span dir="LTR">HIV </span> و الوقاية من و علاج العدوى ب <span dir="LTR">HIV</span>، و في الوقاية من- تأخير ظهور أو تطور- و علاج متلازمة نقص المناعة المكتسبة (<span dir="LTR">AIDS</span>). يمكن استخدام المركبات و أملاحها كمكونات في تركيبات صيدلانية، و بشكل خياري في توليفة مع فيروسات مضادة أو معدلات مناعية أو أجسام مضادة أو لقاحات أخرى.
JOP/2013/0284A 2012-10-08 2013-09-29 مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv JO3470B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012001358 2012-10-08

Publications (1)

Publication Number Publication Date
JO3470B1 true JO3470B1 (ar) 2020-07-05

Family

ID=49354986

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0284A JO3470B1 (ar) 2012-10-08 2013-09-29 مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv

Country Status (47)

Country Link
US (3) US9469634B2 (ar)
EP (3) EP3656384B1 (ar)
JP (2) JP5877281B2 (ar)
KR (1) KR101696128B1 (ar)
CN (1) CN104822670B (ar)
AP (1) AP2015008355A0 (ar)
AR (1) AR092876A1 (ar)
AU (1) AU2013329552B8 (ar)
BR (1) BR112015007742B8 (ar)
CA (1) CA2887312C (ar)
CL (1) CL2015000880A1 (ar)
CO (1) CO7350655A2 (ar)
CR (1) CR20150183A (ar)
CY (2) CY1119655T1 (ar)
DK (3) DK3295942T3 (ar)
DO (1) DOP2015000082A (ar)
EA (1) EA033436B1 (ar)
EC (1) ECSP15018618A (ar)
ES (3) ES2909190T3 (ar)
GE (1) GEP20186838B (ar)
GT (1) GT201500088A (ar)
HK (2) HK1207369A1 (ar)
HR (3) HRP20220502T1 (ar)
HU (3) HUE058903T2 (ar)
IL (1) IL238090B (ar)
JO (1) JO3470B1 (ar)
LT (3) LT2903977T (ar)
MA (1) MA37959A2 (ar)
MD (1) MD4625C1 (ar)
ME (1) ME02918B (ar)
MX (1) MX355040B (ar)
MY (1) MY192716A (ar)
NI (1) NI201500048A (ar)
NO (1) NO2903977T3 (ar)
NZ (1) NZ706729A (ar)
PE (1) PE20151787A1 (ar)
PH (1) PH12015500764B1 (ar)
PL (3) PL3656384T3 (ar)
PT (3) PT3656384T (ar)
RS (3) RS56543B1 (ar)
SG (1) SG11201502620UA (ar)
SI (3) SI3656384T1 (ar)
TN (1) TN2015000106A1 (ar)
TW (2) TWI538907B (ar)
UA (1) UA114006C2 (ar)
WO (1) WO2014058747A1 (ar)
ZA (1) ZA201503143B (ar)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
UY35735A (es) 2013-09-16 2015-04-30 Bayer Pharma AG Trifluorometilpirimidinonas disustituidas y su uso
DK3125894T3 (da) * 2014-04-01 2020-11-16 Merck Sharp & Dohme Prodrugs af hiv-reverstranscriptasehæmmere
ES2901114T3 (es) 2014-08-29 2022-03-21 Tes Pharma S R L Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
US10350165B2 (en) * 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
KR20230095129A (ko) 2016-08-03 2023-06-28 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376A2 (en) 2017-08-30 2020-07-08 President and Fellows of Harvard College High efficiency base editors comprising gam
WO2019055966A2 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2019157087A1 (en) 2018-02-06 2019-08-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
KR20210014108A (ko) 2018-04-30 2021-02-08 리본 테라퓨틱스 인코포레이티드 Parp7 억제제로서의 피리다지논
KR20210069652A (ko) 2018-09-18 2021-06-11 골드핀치 바이오 인코포레이티드 피리다지논 및 이의 사용 방법
AU2019402998B2 (en) * 2018-12-18 2022-12-15 Merck Sharp & Dohme Llc Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells
CN113891937A (zh) 2019-03-19 2022-01-04 布罗德研究所股份有限公司 编辑核苷酸序列的方法和组合物
CA3141143A1 (en) * 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Pyridinone derivatives as selective cytotoxic agents against hiv infected cells
EP4037680A4 (en) * 2019-10-04 2023-10-04 Goldfinch Bio, Inc. BIOMARKER-BASED TREATMENT FOR FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC NEPHROPATHY
US11691969B2 (en) 2019-10-30 2023-07-04 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibtors
JPWO2021107066A1 (ar) 2019-11-28 2021-06-03
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
JP2023543803A (ja) 2020-09-24 2023-10-18 ザ ブロード インスティテュート，インコーポレーテッド プライム編集ガイドｒｎａ、その組成物、及びその使用方法
CA3203876A1 (en) 2021-01-11 2022-07-14 David R. Liu Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
EP4363418A1 (en) * 2021-07-01 2024-05-08 JANSSEN Pharmaceutica NV 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
AU2022325166A1 (en) 2021-08-06 2024-02-08 President And Fellows Of Harvard College Improved prime editors and methods of use
WO2023076898A1 (en) 2021-10-25 2023-05-04 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
WO2023102538A1 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
WO2023205687A1 (en) 2022-04-20 2023-10-26 The Broad Institute, Inc. Improved prime editing methods and compositions
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024077267A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Prime editing methods and compositions for treating triplet repeat disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
RU2000129671A (ru) 1998-04-27 2004-02-20 Сантр Насьональ Де Ля Решерш Сьентифик (Fr) Производные 3-(амино- или аминоалкил) пиридинона и их применение для лечения болезней, связанных с ВИЧ
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
JP4922539B2 (ja) 2000-09-15 2012-04-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
MXPA05008364A (es) 2003-02-07 2005-11-04 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevencion de una infeccion por vih.
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
KR20060124701A (ko) 2004-01-12 2006-12-05 길리애드 사이언시즈, 인코포레이티드 피리미딜 포스포네이트 항바이러스성 화합물 및 그의 사용방법
EP1730120A1 (en) 2004-03-23 2006-12-13 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
AU2005235692B2 (en) 2004-04-23 2011-11-10 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
JP2008525419A (ja) 2004-12-22 2008-07-17 ファイザー・リミテッド Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
CA2625039A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
JP2010510962A (ja) 2006-11-24 2010-04-08 武田薬品工業株式会社 複素単環化合物およびその用途
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
MX2010005483A (es) * 2007-11-20 2010-06-11 Merck Sharp & Dohme Inhibidores de transcriptasa inversa no nucleosidos.
CN103254138A (zh) * 2008-01-08 2013-08-21 默沙东公司 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法
NZ602670A (en) 2010-03-30 2014-09-26 Merck Canada Inc Non-nucleoside reverse transcriptase inhibitors
EP2558093A4 (en) 2010-04-08 2013-10-02 Merck Sharp & Dohme PRODRUGS OF HIV INVERTER TRANSCRIPTASE INHIBITOR
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
DK3125894T3 (da) 2014-04-01 2020-11-16 Merck Sharp & Dohme Prodrugs af hiv-reverstranscriptasehæmmere

Also Published As

Publication number Publication date
NO2903977T3 (ar) 2018-02-17
CA2887312A1 (en) 2014-04-17
PT3656384T (pt) 2022-03-22
HUE048670T2 (hu) 2020-08-28
MD4625B1 (ro) 2019-04-30
DK3656384T3 (da) 2022-04-19
KR101696128B1 (ko) 2017-01-13
MY192716A (en) 2022-09-05
RS59863B1 (sr) 2020-03-31
CA2887312C (en) 2017-02-28
EP2903977B1 (en) 2017-09-20
HUE037231T2 (hu) 2018-08-28
MD20150047A2 (ro) 2015-08-31
AU2013329552B8 (en) 2017-01-12
EP3656384A1 (en) 2020-05-27
JP5877281B2 (ja) 2016-03-02
EA201590674A1 (ru) 2016-02-29
HRP20171819T1 (hr) 2017-12-29
RS56543B1 (sr) 2018-02-28
PL2903977T3 (pl) 2018-01-31
CY1119655T1 (el) 2018-04-04
WO2014058747A1 (en) 2014-04-17
PL3656384T3 (pl) 2022-04-04
AU2013329552A1 (en) 2015-04-16
BR112015007742B1 (pt) 2021-01-19
US20140100231A1 (en) 2014-04-10
GT201500088A (es) 2017-09-28
DK2903977T3 (en) 2017-12-04
MA37959A2 (fr) 2017-12-29
MD4625C1 (ro) 2019-11-30
US9469634B2 (en) 2016-10-18
BR112015007742A2 (pt) 2017-08-08
PH12015500764A1 (en) 2015-07-27
JP6097422B2 (ja) 2017-03-15
ECSP15018618A (es) 2019-06-30
SI3656384T1 (sl) 2022-05-31
MX2015004448A (es) 2016-02-17
MX355040B (es) 2018-03-28
UA114006C2 (xx) 2017-04-10
HUE058903T2 (hu) 2022-09-28
PT3295942T (pt) 2020-02-18
JP2016128470A (ja) 2016-07-14
EA033436B1 (ru) 2019-10-31
CL2015000880A1 (es) 2015-08-28
TW201623256A (zh) 2016-07-01
RS63112B1 (sr) 2022-05-31
PT2903977T (pt) 2017-11-14
CR20150183A (es) 2015-08-10
ZA201503143B (en) 2016-06-29
AU2013329552B2 (en) 2016-09-15
ES2770774T3 (es) 2020-07-03
AP2015008355A0 (en) 2015-04-30
NZ706729A (en) 2018-09-28
ME02918B (me) 2018-10-20
TW201420576A (zh) 2014-06-01
DOP2015000082A (es) 2015-08-16
IL238090B (en) 2019-02-28
CN104822670A (zh) 2015-08-05
HK1252786A1 (zh) 2019-05-31
LT3295942T (lt) 2020-02-10
NI201500048A (es) 2016-06-29
GEP20186838B (en) 2018-04-10
HK1207369A1 (en) 2016-01-29
CY1122585T1 (el) 2021-01-27
CN104822670B (zh) 2018-01-12
HRP20220502T1 (hr) 2022-05-27
AU2013329552C1 (en) 2016-12-22
SI3295942T1 (sl) 2020-03-31
SI2903977T1 (sl) 2017-12-29
LT2903977T (lt) 2017-12-11
US20160145255A1 (en) 2016-05-26
TWI538907B (zh) 2016-06-21
CO7350655A2 (es) 2015-08-10
EP3656384B1 (en) 2022-02-23
PL3295942T3 (pl) 2020-05-18
US10189831B2 (en) 2019-01-29
SG11201502620UA (en) 2015-05-28
EP3295942B1 (en) 2019-11-20
AR092876A1 (es) 2015-05-06
DK3295942T3 (da) 2020-02-10
HRP20200158T1 (hr) 2020-08-07
US20170349585A1 (en) 2017-12-07
TWI598343B (zh) 2017-09-11
PE20151787A1 (es) 2015-12-03
ES2645638T3 (es) 2017-12-07
EP3295942A1 (en) 2018-03-21
TN2015000106A1 (en) 2016-06-29
BR112015007742B8 (pt) 2023-04-25
LT3656384T (lt) 2022-05-10
EP2903977A1 (en) 2015-08-12
US9718819B2 (en) 2017-08-01
JP2015533123A (ja) 2015-11-19
ES2909190T3 (es) 2022-05-05
PH12015500764B1 (en) 2015-07-27
KR20150065186A (ko) 2015-06-12

Similar Documents

Publication Publication Date Title
PH12015500764A1 (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
PH12018500292A1 (en) Antiviral beta-amino acid ester phosphodiame compounds
TN2012000455A1 (en) Non-nucleoside reverse transcriptase inhibitors
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
TN2009000243A1 (en) Non-nucleoside reverse transcriptase inhibitors
WO2008054605A3 (en) Non-nucleoside reverse transcriptase inhibitors
MX2016012915A (es) Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).
EA201170537A1 (ru) Ингибиторы вич-интегразы
WO2015017393A3 (en) Piperazine derivatives as hiv protease inhibitors
WO2011025683A8 (en) Hiv integrase inhibitors
WO2007002481A3 (en) Non-nucleoside reverse transcriptase inhibitors
TN2011000151A1 (en) Hiv integrase inhibitors
UA108495C2 (en) Reverse transcriptase nucleoside inhibitors
CY1116437T1 (el) Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης